Fabi, A., Russillo, M., Ferretti, G., Metro, G., Nisticò, C., Papaldo, P., . . . Cognetti, F. (2012). Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: Efficacy in combination with hormonal therapy. BioMed Central.
استشهاد بنمط شيكاغوFabi, Alessandra, et al. Maintenance Bevacizumab Beyond First-line Paclitaxel Plus Bevacizumab in Patients With Her2-negative Hormone Receptor-positive Metastatic Breast Cancer: Efficacy in Combination With Hormonal Therapy. BioMed Central, 2012.
MLA استشهادFabi, Alessandra, et al. Maintenance Bevacizumab Beyond First-line Paclitaxel Plus Bevacizumab in Patients With Her2-negative Hormone Receptor-positive Metastatic Breast Cancer: Efficacy in Combination With Hormonal Therapy. BioMed Central, 2012.